The test combines serologic, genetic, and inflammation (sgi) markers in its proprietary smart diagnostic algorithm for added diagnostic clarity.

In only one blood test, Prometheus IBD sgi diagnostic facilitates healthcare providers to differentiate IBD vs non-IBD, and Crohn’s disease (CD) vs. ulcerative colitis (UC).

Prometheus president and CEO Joseph Limber said by now combining sgi markers with IBD, they believe this test represents a significant improvement in helping physicians diagnose their patients with suspected IBD.